OutPerformDaily

  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks

Lost Password?

I gave my HomeExchange guest a 5-star review. Then I found heat marks all over my dining table. Do I call her out?

Inside the push to weaken Washington’s toughest financial watchdog

Scared to spend your retirement money? Here’s one way to get over the fear of running out.

It’s ‘unavoidable’: Apple says it will be forced to raise prices due to the AI boom

Did Warsh and Vance just open the door to higher inflation?

Historic NBA Finals ratings and Fox’s $22 billion Roku deal show live sports are key to winning the streaming wars

OutPerformDaily
  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks
OutPerformDaily
  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks
3rdPartyFeeds

Dow Jones Futures Loom After Market Extends Gains; Should You Be Aggressive?

May 29, 2022

The major indexes snapped weekly losing streaks as a confirmed market rally added to gains Friday. How aggressive should you be? Read More...

3rdPartyFeeds

Advertising industry titan ‘puzzled’ by Musk’s plan for Twitter

May 29, 2022

S4 Capital founder Sir Martin Sorrell talks with Yahoo Finance Live about the state of the advertising industry as Snap sends a big warning. Read More...

3rdPartyFeeds

1 Fintech Stock That Could be a Great Niche Play for Your Portfolio

May 29, 2022

Since its IPO last June, dLocal (NASDAQ: DLO) has enjoyed an impressive year on many fronts. In this video clip from the "Future of Fintech" on Motley Fool...

3rdPartyFeeds • News

: A new generation of ulcerative colitis drugs is in development. Will they be blockbusters for Lilly and Pfizer?

May 29, 2022

Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.

Read More...

3rdPartyFeeds • News

: Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting

May 29, 2022

This includes Arcellx, Iovance Biotherapeutics, and ZymeWorks.

Read More...

3rdPartyFeeds • News

Outside the Box: 3 ways Russia’s war in Ukraine could end — and even a Ukraine victory brings danger

May 29, 2022

Depending on how long the war continues, the economic impact could be even worse for the developing world than the 2008 financial crisis.

Read More...

3rdPartyFeeds • News

Help Me Sleep: 5 best cooling comforters, according to sleep coaches and professional reviewers

May 29, 2022

We asked sleep coaches and experts to share their favorite cooling comforters and duvets.

Read More...

3rdPartyFeeds • News

Mutual Funds Weekly: These money and investing tips are tools to help fix your broken portfolio

May 29, 2022

Money and investing stories popular with MarketWatch readers over the past week.

Read More...

3rdPartyFeeds

Should You Buy Snap Stock After It Crashed?

May 29, 2022

Snap's stock dropped by more than 40% after the company hinted that headwinds worsened in the last month. Read More...

3rdPartyFeeds

Here’s Why Alphabet Is Even Cheaper Than It Looks

May 29, 2022

Year to date, Alphabet is down nearly 27%, based on fears of a cyclical slowdown in advertising dollars. With pessimism now being extrapolated across the...

Previous 1 … 2,992 2,993 2,994 2,995 2,996 … 8,455 Next
Indices by TradingView

Categories

  • 3rdPartyFeeds
  • Cannabis Stocks
  • Index Funds
  • International
  • News
  • Short
  • Stock Picks
  • Tech Stocks
  • Uncategorized
Indices by TradingView
While subscribers receive the benefit of Outperformdaily opinions, none of the information contained therein constitutes a recommendation from Outperformdaily that any particular security, portfolio of securities, transaction, option, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Outperformdaily may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Outperformdaily’s past results are not necessarily indicative of future performance. All investments are subject to loss. Our employees and writters typically personally invest in all recommendations, but they are not obligated too. Our employees and writters are prohibited from taking an opposite position from which they write about.